Kumashiro N, Erion DM, Zhang D, Kahn M, Beddow SA, Chu X, Still CD, Gerhard GS, Han X, Dziura J, Petersen KF, Samuel VT, Shulman GI (2011) Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease
Patients using CJC 1295 ipamorelin for weight loss typically see abdominal fat reductions over 8 to 12 weeks when combined with proper nutrition and exercise
Background care (concomitant use of statins, angiotensin converting enzyme inhibitors /angiotensin receptor blockers, beta-blockers and dual antiplatelet therapy) may also play a role in this discrepancy
It increases natural GH and IGF-1 secretion, especially when paired with a GH secretagogue like Ipamorelin